Trial results

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

NCT06716424 on ClinicalTrials.gov · last registry update 2026-07-10

Finished 12 June 2026, after enrolling 105 people. Primary outcome, as filed: Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs). lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

105

Started

2025-01-06

Primary completion

2026-06-12 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.